TECH Financials Bio-Techne

10 years of revenue, profit, cash flow and balance-sheet history through FY2026, from SEC filings — with a computed, factual read of the trend. Updated 20 d ago Overview →

Growth & profitability

Revenue has grown 5.5% per year over the past 5 years.
Net income has grown in line with revenue (5.4% vs 5.5% per year).
Operating margin has contracted, at 20.7% in the latest year.
Free cash flow has declined 3.1% per year over the past 5 years.

Financial health

Operating income covered interest expense 26× in the latest year.

Shareholder returns

Dividends have been paid for 10 consecutive years, consuming 27.4% of earnings and 19.0% of free cash flow.
The dividend has grown 0.1% per year over the past 5 years.

Revenue & net income

RevenueNet income

Margins (gross / operating / net)

GrossOperatingNet

Return on equity & assets (ROE / ROA)

ROEROA

Free cash flow (CFO − capex)

Free cash flow

Cash vs total debt

CashTotal debt

Cash flow: operating / investing / financing

OperatingInvestingFinancing

Key annual figures

FY	Revenue	Net income	Gross M	Op M	ROE	ROA	FCF	Total debt	Cash
2026	$1.2B	$182M	65.8%	20.7%	8.6%	7.0%	$263M	—	$265M
2025	$1.2B	$73M	64.8%	8.4%	3.8%	2.9%	$257M	—	$162M
2024	$1.2B	$168M	66.4%	17.8%	8.1%	6.2%	$236M	—	$152M
2023	$1.1B	$285M	67.7%	26.3%	14.5%	10.8%	$216M	—	$181M
2022	$1.1B	$263M	68.4%	26.8%	15.5%	11.5%	$280M	—	$173M
2021	$931M	$140M	68.0%	25.5%	8.9%	6.2%	$308M	—	$199M
2020	$739M	$229M	65.4%	21.3%	16.6%	11.3%	$153M	—	$147M
2019	$714M	$96M	66.3%	20.5%	8.2%	5.1%	$156M	—	$101M
2018	$643M	—	67.2%	21.2%	0.0%	0.0%	$149M	—	$122M
2017	$563M	—	66.5%	21.4%	0.0%	0.0%	$129M	—	$92M

Revenue & net income

RevenueNet income

Margins (gross / operating / net)

GrossOperatingNet

Return on equity & assets (ROE / ROA)

ROEROA

Free cash flow (CFO − capex, quarterly)

Free cash flow

Cash vs total debt

CashTotal debt

Cash flow: operating / investing / financing

OperatingInvestingFinancing

Key quarterly figures

Quarter	Revenue	Net income	Gross M	Op M	ROE	ROA	FCF	Total debt	Cash
Jun '26	$321M	$55M	65.8%	23.1%	2.6%	2.1%	$87M	—	$265M
Mar '26	$311M	$51M	66.9%	24.2%	2.4%	2.0%	$78M	—	$210M
Dec '25	$296M	$38M	64.6%	18.4%	1.9%	1.5%	$76M	—	$173M
Sep '25	$287M	$38M	65.6%	16.6%	—	1.5%	$22M	—	$145M
Jun '25	$317M	-$18M	62.7%	-7.5%	-0.9%	-0.7%	$93M	—	$162M
Mar '25	$316M	$23M	67.9%	12.2%	1.1%	0.9%	$31M	—	$141M
Dec '24	$297M	$35M	65.3%	16.0%	1.7%	1.3%	$78M	—	$178M
Sep '24	$289M	$34M	63.2%	13.8%	1.6%	1.2%	$55M	—	$188M
Jun '24	$306M	$41M	66.4%	15.0%	2.0%	1.5%	$58M	—	$152M
Mar '24	$303M	$49M	67.4%	22.1%	2.4%	1.8%	$65M	—	$140M
Dec '23	$273M	$27M	64.8%	13.9%	1.4%	1.0%	$68M	—	$130M
Sep '23	$277M	$51M	66.9%	20.2%	2.6%	1.9%	$46M	—	$149M
Jun '23	$301M	$75M	67.9%	31.4%	3.8%	2.9%	$73M	—	$181M
Mar '23	$294M	$70M	68.7%	27.3%	3.7%	2.7%	$39M	—	$127M
Dec '22	$272M	$50M	67.5%	25.0%	2.7%	2.1%	$58M	—	$165M
Sep '22	$270M	$90M	66.6%	20.9%	5.1%	3.8%	$47M	—	$165M
Jun '22	$288M	$62M	69.5%	28.0%	3.6%	2.7%	$89M	—	$173M
Mar '22	$290M	$60M	69.4%	31.1%	3.5%	2.6%	$58M	—	$161M
Dec '21	$269M	$72M	68.2%	23.2%	4.2%	3.1%	$91M	—	$212M
Sep '21	$258M	$69M	66.4%	24.5%	4.2%	3.0%	$42M	—	$196M

Valuation over time

How the market has priced TECH against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.

The price-to-earnings ratio has risen from 44.2× (Mar '23) to 62.5× (Sep '26).
The price-to-sales ratio has fallen from 10.5× (Mar '23) to 9.4× (Sep '26).
The dividend yield has risen from 0.4% (Mar '23) to 0.4% (Sep '26).

Price / earnings (P/E)

P/E

Price / sales (P/S)

P/S

Dividend yield (%)

Dividend yield %

Frequently asked questions

Is TECH growing its revenue and profit?

Over the past 5 years, Bio-Techne's revenue has grown 5.5% per year, and net income grown 5.4% per year. These are computed facts, not advice.

How much debt does TECH have?

As of FY2026, Bio-Techne reported — of total debt against $265M of cash; operating income covered interest expense 26×.

What is TECH's profit margin?

In FY2026, gross margin was 65.8%, operating margin 20.7%, and net margin 15.0%.

What is TECH's P/E ratio?

As of Sep '26, Bio-Techne traded at a price-to-earnings ratio of about 62.5× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S and dividend yield have moved with the share price. These are computed facts, not advice.

Where does this data come from?

All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.

Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.